Laam dose comparison: A clinical trial

R. E. Johnson, T. Eissenberg, Eric C Strain, S. L. Walsh, Robert Brooner, I. A. Liebson, Maxine L Stitzer, George Bigelow

Research output: Contribution to journalArticle

Abstract

LAAM is the most recently approved pharmacotherapy for opioid dependence. To date, there have been no clinical trials assessing the dose effectiveness of LAAM. Purpose: To assess the effectiveness of three LAAM dose conditions. Methods: Opioid-dependent subjects (N=180) were stratified and randomly assigned to a 29 wk double-blind clinical trial comparing three, thrice-weekly (M/W/F) LAAM dose conditions. Subjects in the low (N=62), medium (N=59), and high (N=59) dose conditions received 25/25/35, 50/50/70, and 100/100/140 mg, respectively. Primary outcome measures assessed through the maintenance period (wk 17) were: 1) overall percent negative (a) opioid and (b) cocaine urine specimens, 2) percent of subjects with 12 consecutive opioid negative urine specimens, and 3) treatment retention. Results: Significant differences were observed across conditions for measures 1a and 2. Overall urine specimens negative for opioids were, 23.1%, 32.4%, and 40.8% and the percent of patients able to provide 12 consecutive opioid negative urine specimens were 11%, 20%, and 32% for the low, medium, and high dose conditions, respectively. There were no differences between conditions for measures 1b and 3. Conclusion: The effectiveness of LAAM treatment on rates of opioid negative urine specimens increases with increasing LAAM dose.

Original languageEnglish (US)
Pages (from-to)189
Number of pages1
JournalClinical Pharmacology and Therapeutics
Volume61
Issue number2
StatePublished - 1997

Fingerprint

Methadyl Acetate
Opioid Analgesics
Clinical Trials
Urine
Cocaine
Maintenance
Outcome Assessment (Health Care)
Drug Therapy

ASJC Scopus subject areas

  • Pharmacology

Cite this

Johnson, R. E., Eissenberg, T., Strain, E. C., Walsh, S. L., Brooner, R., Liebson, I. A., ... Bigelow, G. (1997). Laam dose comparison: A clinical trial. Clinical Pharmacology and Therapeutics, 61(2), 189.

Laam dose comparison : A clinical trial. / Johnson, R. E.; Eissenberg, T.; Strain, Eric C; Walsh, S. L.; Brooner, Robert; Liebson, I. A.; Stitzer, Maxine L; Bigelow, George.

In: Clinical Pharmacology and Therapeutics, Vol. 61, No. 2, 1997, p. 189.

Research output: Contribution to journalArticle

Johnson, RE, Eissenberg, T, Strain, EC, Walsh, SL, Brooner, R, Liebson, IA, Stitzer, ML & Bigelow, G 1997, 'Laam dose comparison: A clinical trial', Clinical Pharmacology and Therapeutics, vol. 61, no. 2, pp. 189.
Johnson RE, Eissenberg T, Strain EC, Walsh SL, Brooner R, Liebson IA et al. Laam dose comparison: A clinical trial. Clinical Pharmacology and Therapeutics. 1997;61(2):189.
Johnson, R. E. ; Eissenberg, T. ; Strain, Eric C ; Walsh, S. L. ; Brooner, Robert ; Liebson, I. A. ; Stitzer, Maxine L ; Bigelow, George. / Laam dose comparison : A clinical trial. In: Clinical Pharmacology and Therapeutics. 1997 ; Vol. 61, No. 2. pp. 189.
@article{fd8b25170c4c465e8e032a6d9d12b97f,
title = "Laam dose comparison: A clinical trial",
abstract = "LAAM is the most recently approved pharmacotherapy for opioid dependence. To date, there have been no clinical trials assessing the dose effectiveness of LAAM. Purpose: To assess the effectiveness of three LAAM dose conditions. Methods: Opioid-dependent subjects (N=180) were stratified and randomly assigned to a 29 wk double-blind clinical trial comparing three, thrice-weekly (M/W/F) LAAM dose conditions. Subjects in the low (N=62), medium (N=59), and high (N=59) dose conditions received 25/25/35, 50/50/70, and 100/100/140 mg, respectively. Primary outcome measures assessed through the maintenance period (wk 17) were: 1) overall percent negative (a) opioid and (b) cocaine urine specimens, 2) percent of subjects with 12 consecutive opioid negative urine specimens, and 3) treatment retention. Results: Significant differences were observed across conditions for measures 1a and 2. Overall urine specimens negative for opioids were, 23.1{\%}, 32.4{\%}, and 40.8{\%} and the percent of patients able to provide 12 consecutive opioid negative urine specimens were 11{\%}, 20{\%}, and 32{\%} for the low, medium, and high dose conditions, respectively. There were no differences between conditions for measures 1b and 3. Conclusion: The effectiveness of LAAM treatment on rates of opioid negative urine specimens increases with increasing LAAM dose.",
author = "Johnson, {R. E.} and T. Eissenberg and Strain, {Eric C} and Walsh, {S. L.} and Robert Brooner and Liebson, {I. A.} and Stitzer, {Maxine L} and George Bigelow",
year = "1997",
language = "English (US)",
volume = "61",
pages = "189",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Laam dose comparison

T2 - A clinical trial

AU - Johnson, R. E.

AU - Eissenberg, T.

AU - Strain, Eric C

AU - Walsh, S. L.

AU - Brooner, Robert

AU - Liebson, I. A.

AU - Stitzer, Maxine L

AU - Bigelow, George

PY - 1997

Y1 - 1997

N2 - LAAM is the most recently approved pharmacotherapy for opioid dependence. To date, there have been no clinical trials assessing the dose effectiveness of LAAM. Purpose: To assess the effectiveness of three LAAM dose conditions. Methods: Opioid-dependent subjects (N=180) were stratified and randomly assigned to a 29 wk double-blind clinical trial comparing three, thrice-weekly (M/W/F) LAAM dose conditions. Subjects in the low (N=62), medium (N=59), and high (N=59) dose conditions received 25/25/35, 50/50/70, and 100/100/140 mg, respectively. Primary outcome measures assessed through the maintenance period (wk 17) were: 1) overall percent negative (a) opioid and (b) cocaine urine specimens, 2) percent of subjects with 12 consecutive opioid negative urine specimens, and 3) treatment retention. Results: Significant differences were observed across conditions for measures 1a and 2. Overall urine specimens negative for opioids were, 23.1%, 32.4%, and 40.8% and the percent of patients able to provide 12 consecutive opioid negative urine specimens were 11%, 20%, and 32% for the low, medium, and high dose conditions, respectively. There were no differences between conditions for measures 1b and 3. Conclusion: The effectiveness of LAAM treatment on rates of opioid negative urine specimens increases with increasing LAAM dose.

AB - LAAM is the most recently approved pharmacotherapy for opioid dependence. To date, there have been no clinical trials assessing the dose effectiveness of LAAM. Purpose: To assess the effectiveness of three LAAM dose conditions. Methods: Opioid-dependent subjects (N=180) were stratified and randomly assigned to a 29 wk double-blind clinical trial comparing three, thrice-weekly (M/W/F) LAAM dose conditions. Subjects in the low (N=62), medium (N=59), and high (N=59) dose conditions received 25/25/35, 50/50/70, and 100/100/140 mg, respectively. Primary outcome measures assessed through the maintenance period (wk 17) were: 1) overall percent negative (a) opioid and (b) cocaine urine specimens, 2) percent of subjects with 12 consecutive opioid negative urine specimens, and 3) treatment retention. Results: Significant differences were observed across conditions for measures 1a and 2. Overall urine specimens negative for opioids were, 23.1%, 32.4%, and 40.8% and the percent of patients able to provide 12 consecutive opioid negative urine specimens were 11%, 20%, and 32% for the low, medium, and high dose conditions, respectively. There were no differences between conditions for measures 1b and 3. Conclusion: The effectiveness of LAAM treatment on rates of opioid negative urine specimens increases with increasing LAAM dose.

UR - http://www.scopus.com/inward/record.url?scp=33748955771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748955771&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748955771

VL - 61

SP - 189

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -